CONTACT

Thank you for your interest in Boehringer Ingelheim's Oncology Pipeline.
We know, that there may not yet be all questions you may have answered. Please contact us.

WE WELCOME YOUR FEEDBACK

Julia Meyer-Kleinmann
Director Corporate Communications

Boehringer Ingelheim GmbH

email me

Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.

† Not an official event of the 2012 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Boehringer Ingelheim on